hydralazine has been researched along with gabexate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, M; Hayata, M; Kadowaki, D; Kakizoe, Y; Kitamura, K; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Narita, Y; Sakai, Y; Shiraishi, N; Uchimura, K; Ueda, M | 1 |
1 other study(ies) available for hydralazine and gabexate
| Article | Year |
|---|---|
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Esters; Fibrosis; Free Radical Scavengers; Gabexate; Guanidines; Hydralazine; Kidney; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Serine Proteinase Inhibitors | 2015 |